克柔念珠菌对抗真菌药物耐药机制的研究进展

中国真菌学杂志　 2012, Vol. 7 　Issue (1): 55-58.

克柔念珠菌对抗真菌药物耐药机制的研究进展

乔祖莎, 冯文莉

山西医科大学第二医院皮肤性病科, 太原030001

收稿日期:2011-09-27 出版日期:2012-02-28 发布日期:2012-02-28
通讯作者: 冯文莉,E-mail:fwl92@hotmail.com E-mail:fwl92@hotmail.com
作者简介:乔祖莎,女(汉族),硕士研究生在读.E-mail:qiaozusha007@163.com
基金资助:
山西医科大学科技创新基金(01201013)

Advances in research on mechanisms for drug resistance of Candida krusei

QIAO Zu-sha, FENG Wen-li

Department of Dermatovenereology, the Second Hospital of Shanxi Medical University, Taiyuan 030001, China

Received:2011-09-27 Online:2012-02-28 Published:2012-02-28

摘要/Abstract

摘要： 近年来,克柔念珠菌感染明显增加,对抗真菌药物尤其是唑类药物的耐药现象越来越严重,深入研究其耐药机制已引起高度关注。克柔念珠菌耐药机制可能与以下因素有关:唑类药物作用靶酶结构的改变、真菌细胞膜上外排泵过度表达、真菌细胞内药物蓄积减少等。克柔念珠菌对唑类的耐药可能是多种耐药机制共同作用的结果。

关键词: 克柔念珠菌, 抗真菌药, 耐药, 分子机制

Abstract: Invasive infections of Candida krusei increased in recent years contributed to the resistance to fuconazole.The mechanism of resistance in C.krusei may be a variety of drug-resistant possibilities including changed structure of cytochrome P450 sterol 14-demethylase in fungal cell,overexpression of efflux pumps,and reduced intracellular drug accumulation.

Key words: Candida krusei, antifungal drug, drug resistant, molecular mechanisms

中图分类号:

R379.4

乔祖莎, 冯文莉. 克柔念珠菌对抗真菌药物耐药机制的研究进展[J]. 中国真菌学杂志, 2012, 7(1): 55-58.

QIAO Zu-sha, FENG Wen-li. Advances in research on mechanisms for drug resistance of Candida krusei[J]. Chinese Journal of Mycology, 2012, 7(1): 55-58.

参考文献

[1] Dimopoulos G,Karabinis A,Samonis G,et al.Candidemia in im-munocompromised and immunocompetent critically ill patients:aprospective comparative study[J].Eur J Clin Microbiol InfectDis,2007,26(6):377-384.
[2] Lamping E,Ranchod A,Nakamura K,et al.Abc1p is a multidrugefflux transporter that tips the balance in favor of innate azole re-sistance in Candida krusei[J].Antimicrob Agents Chemother,2009,53(2):354-369.
[3] Cuenca-Estrella M,Gomez-Lopez A,Cuesta l,et al.Frequencyof resistance in vitro to voriconazole among spanish clinical iso-lates of Candida spp.according to breakpoints by the AntifungalSubcommittee of the European Committee on antimicrobial sus-ceptibility testing[J].Antimicrob Agents Chemother,2011,55(4):1794-1797.
[4] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the AR-TEMIS DISK global antifungal surveillance study,1997 to2005:an 8.5-year analysis of susceptibilities of Candida speciesand other yeast species to fluconazole and voriconazole deter-mined by CLSI standardized disk diffusion testing[J].Clin Mi-crobiol,2007,45(6):1735-1745.
[5] Pfaller MA,Diekema DJ,Gibbs DL,et al.Results from the AR-TEMIS DISK global antifungal surveillance study,1997 to 2007:a 10.5-year analysis of susceptibilities of Candida species to flu-conazole and voriconazole determined by CLSI standardized diskdiffusion[J].J Clin Microbiology,2010,48(4):1366-1377.
[6] Clark FS,Parkinson T,Hitchcock CA,et al.Correlation betweenrhodamine 123 accumulation and azole sensitivity in Candidaspecies:possible role for drug efflux in drug resistance[J].An-timicrobial Agents Chemother,1996,40(2):419-425.
[7] Orozco AS,Higginbotham LM,Hitchcock CA,et al.Mechanismof fluconazole resistance in Candida krusei[J].Antimicrob A-gents Chemother,1998,42(10):2645-2649.
[8] Sanglard D,Ischer F,Parkinson T,et al.Candida albicans mu-tations in the ergosterol biosynthetic pathway and resistance toseveral antifungal agents[J].Antimicrob Agents Chemother,2003,47(8):2404-2412.
[9] Marichal P,Gorrens J,Coene MC,et al.Origin of differences insusceptibility of Candida krusei to azole antifungal agents[J].Mycoses,1995,38(3-4):111-117.
[10] Miyazaki T,Miyazaki Y,Izumikawa K,et al.Fluconazoletreatment is effective against a Candida albicans erg3/erg3 mu-tant in vivo despite in vitro resistance[J].Antimicrob AgentsChemother,2006,50(2):580-586.
[11] Kanafani ZA,Perfect JR.Antimicrobial resistance:resistance toantifungal agents:mechanisms and clinical impact[J].Clin In-fect Dis,2008,46(1):120-128.
[12] Martel CM,Parker JE,Bader O,et al.Identification and char-acterization of four azole-resistant erg3 mutants of Candidaalbicans[J].Antimicrob Agents Chemother,2010,54(11):4527-4533.
[13] Venkateswarlu K,Denning DW,Manning NJ,et al.Reducedaccumulation of drug in Candida krusei accounts for itracon-azole resistance[J].Antimicrob Agents Chemother,1996,40(11):2443-2446.
[14] Katiyar SK,Edlind TD.Identification and expression of multi-drug resistance-related ABC transporter genes in Candidakrusei[J].Med Mycol,2001,39(1):109-116.
[15] Guinea J,Sanchez-Somolinos M,Cuevas O,et al.Fluconazole re-sistance mechanisms in Candida krusei:the contribution of ef-flux-pumps[J].Med Mycol,2006,44(6):575-578.
[16] Mansfield BE,Oltean HN,Oliver BG,et al.Azole drugs areimported by facilitated diffusion in Candida albicans and otherpathogenic fungi[J].PLoS Pathog,2010,6(9):e1001126.
[17] Hitchcock CA,Barrett-Bee KJ,Russell NJ.The lipid composi-tion and permeability to the triazole antifungal antibiotic ICI153066 of serum-grown mycelial cultures of Candida albicans[J].J Gen Microbiol,1989,135(7):1949-1955.
[18] Niimi M,Firth NA,Cannon RD.Antifungal drug resistance of o-ral fungi[J].Odontology,2010,98(1):15-25.
[19] Nickerson KW,Atkin AL,Hornby JM.Quorum sensing in dimor-phic fungi:farnesol and beyond[J].Appl Environ Microbiol,2006,72(6):3805-3813.
[20] Mukherjee PK,Chandra J,Kuhn DM,et al.Mechanism of flu-conazole resistance in Candida albicans biofilms:phase specificrole of efflux pumps and membrane sterols[J].Infect Immun,2003,71(8):4333-4340.
[21] Walker LA,Gow NA,Munro CA.Fungal echinocandin resistance[J].Fungal Genet Biol,2010,47(2):117-126.
[22] Pfaller MA,Diekama DJ.Epidemiology of invasive candidiasis:a persistent public health problem[J].Clin Microbiol Rev,2007,20(1):133-163.
[23] Kahn JN,Garcia-Effron G,Hsu MJ,et al.Acquired echinocan-din resistance in a Candida krusei isolate due to modification ofglucan synthase[J].Antimicrob Agents Chemother,2007,51(5):1876-1878.